Author

S. W. Fanning

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Approach:biophysical modeling· 1 Research Focus:cancer & tumor microenvironment· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

D. J. Hosfield· 2 shared G. L. Greene· 2 shared M. Laine· 2 shared A. Das Gupta· 1 shared A. J. Smith· 1 shared A. T. Nelczyk· 1 shared C. D. Torrice· 1 shared C. E. Fowler· 1 shared

Activity by Year

2018-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. J. Hosfield

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Re-education of myeloid immune cells to reduce regulatory T cell expansion and impede breast cancer progression

H. E. V. Gamage, S. H. Shahoei, S. T. Albright, Y. Wang, A. J. Smith, R. Farmer, E. C. Fink, E. Jacquin, E. Weisser, R. O. Bautista, M. A. Henn, C. P. Schane, A. T. Nelczyk, L. Ma, A. Das Gupta, , E. R. Nelson

This paper shows that NR0B2 in myeloid cells reduces Treg expansion and tumor growth by modulating the NLRP3 inflammasome, with small molecule agonists improving ICB efficacy in breast cancer.

bioRxiv · Aug 14, 2023 · PreprintCancer Biology

A new chemotype of chemically tractable nonsteroidal estrogens based on a thienopyrimidine core.

V. R. Sammeta, J. D. Norris, S. Artham, C. D. Torrice, J. Byemerwa, C. Joiner, S. W. Fanning, D. P. McDonnell, T. M. Willson

The paper identifies a new chemotype of nonsteroidal estrogens based on a thienopyrimidine core through targeted screening and structure-guided optimization.

bioRxiv · Apr 15, 2022Cell Biology

Stereo-specific Lasofoxifene Derivatives Reveal the Interplay between Estrogen Receptor Alpha Stability and Antagonistic Activity in ESR1 Mutant Breast Cancer Cells

D. J. Hosfield, S. Weber, N.-S. Li, M. Suavage, E. Sullivan, E. Nduwke, R. Han, S. Cush, M. Laine, S. C. Mader, G. L. Greene, S. W. Fanning

The paper synthesizes lasofoxifene derivatives to study how ER cellular lifetime and antagonistic activity relate in ESR1 mutant breast cancer cells, finding that reducing ER lifetime does not always enhance transcriptional antagonism.

bioRxiv · Aug 27, 2021Cancer Biology

The SERM/SERD Bazedoxifene Disrupts ESR1 Helix 12 to Overcome Acquired Hormone Resistance in Breast Cancer Cells

S. W. Fanning, R. Jeselsohn, V. Dharmarajan, C. G. Mayne, M. Karimi, G. Buchwalter, R. Houtman, W. Toy, C. E. Fowler, M. Laine, K. E. Carlson, T. A. Martin, J. Nowak, J. C. Nwachukwu, D. J. Hosfield, , G. L. Greene

This study shows that bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells by inhibiting Y537S and D538G ER mutants more effectively than tamoxifen.

bioRxiv · Apr 23, 2018Cancer Biology